Sign In
Buy ARGX
$844.50
+13.71 (+1.65%)
At Close: Aug 04, 2026
argenx: Vyvgart Continues To Perform Well, Key Pipeline Catalyst Next Quarter
10:04pm, Sunday, 30'th Oct 2022
Vyvgart once again exceeded sales expectations by generating $131.3 million in net sales in the third quarter. Potential approval of subcutaneous Vyvgart in 1H 2023 and geographic expansion should fue
McDonald's To Rally Over 13%? Here Are 5 Other Price Target Changes For Friday
11:34am, Friday, 28'th Oct 2022 Benzinga
Wedbush raised McDonald's Corporation (NYSE: MCD) price target from $265 to $300. Wedbush analyst Nick Setyan maintained the stock with an Outperform rating. McDonald's shares rose 3.3% to close at $
Why Earnings Season Could Be Great for argenx (ARGX)
12:46pm, Wednesday, 26'th Oct 2022 Zacks Investment Research
argenx (ARGX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
4 Biotech Stocks Set to Outpace Q3 Earnings Estimates
01:11pm, Friday, 21'st Oct 2022 Zacks Investment Research
Let us take a look at some biotech stocks, ARGX, BMRN, LLY and GMAB, which are poised to beat on third-quarter earnings.
4 Biotech Stocks Set to Outpace Q3 Earnings Estimates
10:32am, Friday, 21'st Oct 2022
Let us take a look at some biotech stocks, ARGX, BMRN, LLY and GMAB, which are poised to beat on third-quarter earnings.
argenex SE (ARGX) Upgraded to Buy: Here's Why
04:00pm, Thursday, 20'th Oct 2022 Zacks Investment Research
argenex SE (ARGX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
argenex SE (ARGX) Upgraded to Buy: Here's Why
01:33pm, Thursday, 20'th Oct 2022
argenex SE (ARGX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
argenx to Report Third Quarter 2022 Financial Results and Business Update on October 27, 2022
05:00am, Thursday, 20'th Oct 2022 GlobeNewswire Inc.
October 20, 2022Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today
argenx to Report Third Quarter 2022 Financial Results and Business Update on October 27, 2022
01:00am, Thursday, 20'th Oct 2022
October 20 , 2022 Amsterdam , the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, to
7 Analysts Have This to Say About argenx
01:25pm, Tuesday, 18'th Oct 2022 Benzinga
argenx (NASDAQ:ARGX) has observed the following analyst ratings within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
1
5
1
0
0
Last 30D
0
1
0
Benzinga's Top Ratings Upgrades, Downgrades For October 12, 2022
02:02pm, Wednesday, 12'th Oct 2022 Benzinga
Upgrades
For CME Group Inc (NASDAQ:CME), Deutsche Bank upgraded the previous rating of Hold to Buy. In the second quarter, CME Group showed an EPS of $1.97, compared to $1.64 from the year-ago quarte
Is Argenx (ARGX) Outperforming Other Medical Stocks This Year?
01:40pm, Friday, 07'th Oct 2022 Zacks Investment Research
Here is how argenex SE (ARGX) and McKesson (MCK) have performed compared to their sector so far this year.
Is Argenx (ARGX) Outperforming Other Medical Stocks This Year?
11:17am, Friday, 07'th Oct 2022
Here is how argenex SE (ARGX) and McKesson (MCK) have performed compared to their sector so far this year.
Tracking Ron Baron's BAMCO Portfolio - Q2 2022 Update
04:53am, Monday, 03'rd Oct 2022 Seeking Alpha
Ron Baron's 13F portfolio value decreased from $40.75B to $31.14B this quarter. Click here to read more about BAMCO's holdings and trades for Q2 2022.
Immunovant's New Candidate Provides Some Strategic Flexibility & Clarity, Analysts Say
06:36pm, Thursday, 29'th Sep 2022 Benzinga
On Wednesday, Immunovant Inc (NASDAQ: IMVT) announced a new anti-FcRn, IMVT-1402, at Roivant Sciences Ltd's (NASDAQ: ROIV) Investor Day.
IMVT-1402 is a new anti-FcRn monoclonal antibody that mat
